The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)-Reference-Cited by-同舟云学术

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Published:2019-12 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Rini Brian I.,Battle Dena,Figlin Robert A.,George Daniel J.,Hammers Hans,Hutson Tom,Jonasch Eric,Joseph Richard W.,McDermott David F.,Motzer Robert J.,Pal Sumanta K.,Pantuck Allan J.,Quinn David I.,Seery Virginia,Voss Martin H.,Wood Christopher G.,Wood Laura S.,Atkins Michael B.^ORCID

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0813-8.pdf

Reference69 articles.

1. Xu JX, et al. FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-Angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017;22(3):311–7.

2. Rini BI, et al. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016;4:81.

3. Institute of Medicine (U.S.). Committee on standards for developing trustworthy clinical practice guidelines. In: Graham R, editor. Clinical practice guidelines we can trust. Washington, DC: National Academies Press; 2011. p. xxxiv. 266 p.

4. Kaufman HL, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98.

5. Hammers HJ, et al. Safety and efficacy of Nivolumab in combination with Ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol. 2017;35(34):3851–8.

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

2. Comprehensive analysis of LD-related genes signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma;BMC Nephrology;2024-09-10

3. The Anti‐Metastatic Action of Oxyresveratrol via Suppression of Phosphoryl‐ERK/‐PKCα‐Mediated Sp1/MMP1 Signaling in Human Renal Carcinoma Cells;Environmental Toxicology;2024-08-22

4. Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment;Patient Preference and Adherence;2024-08

5. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial;Annals of Oncology;2024-08